FinnCap restated their corporate rating on shares of Synairgen plc (LON:SNG) in a research report sent to investors on Wednesday.

Synairgen plc (LON:SNG) opened at 11.25 on Wednesday. The company’s 50-day moving average price is GBX 7.97 and its 200 day moving average price is GBX 15.07. Synairgen plc has a 1-year low of GBX 6.98 and a 1-year high of GBX 36.00. The firm’s market capitalization is GBX 10.28 million.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/09/synairgen-plcs-sng-corporate-rating-reiterated-at-finncap.html.

About Synairgen plc

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease.

Receive News & Stock Ratings for Synairgen plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen plc and related stocks with our FREE daily email newsletter.